retatrutide ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide - PeptivaPro US

This helps improve comfort during early treatment phases

Brand-Name FDA-Approved Medications Referenced on altRx altRx's source materials also reference brand-name FDA-approved medications at separate listed price points: Mounjaro: Listed at $1,249 per month per altRx's source materials Ozempic: Listed at $1,149 per month per altRx's source materials Wegovy: Listed at $1,579 per month per altRx's source materials Zepbound: Listed at $1,249 per month per altRx's source materials According to altRx's published trademark notice, Wegovy is FDA-approved for weight loss, and Ozempic is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss at the discretion of a clinician

no documented clinical interaction of this type has been reported

doi: 10.1186/s13024-015-0029-4 210 KellDBPretoriusE